Dr. Ben-Tsion Williger

Dr. Ben-Tsion Williger , the CEO of CapsuTech, comes from the fields of cancer research and has a firm scientific experience. Dr. Williger served in several biotechnology companies as a Research Team Head, Department Head and CEO of CancerTek Pharmaceuticals. In his last position as the CEO of BWP Dr. Williger provided technological and business development support to early stage biotechnology and medical device companies.

"We are screening for compounds that inhibit MMP-9 expression by working at the lipase level," says Dr. Ben-Tsion Williger, General Manager of CancerTek

Dr Ben-Tsion Williger, CancerTek Pharmaceuticals Ltd, ISRAEL

CancerTek Pharmaceuticals is a young, private biotechnology company with 5 employees, currently based in the Incentive Technology Incubator.It was founded by Dr Ben-Tsion Williger in May 2001 and is dedicated to the development of anti-cancer therapeutics based on targeting the pathway of MMP-9 synthesis.

Dr. Ben-Tsion Williger

Dr. Williger accomplished his Bachelor degree in life sciences in Bar-Ilan University during which he was awarded by the Knesset of Israel (the Israeli Parliament) for excellent achievements in studies.After moving to the Weizmann Institute of Science Dr. Williger gained his Masters in the Department of Chemical Immunology.He conducted his doctorate studies under the supervision of Prof. M. Liscovitch, concentrating on the biological role of phosphatidic acid in healthy and cancer cells.Upon accomplishment of his Ph.D. studies Dr. Williger started a three year research period in the laboratory of Prof. J.H. Exton (Dept. of Molecular Physiology and Biophysics, School of Medicine, Vanderbilt University) further focusing on the cellular role of phospholipase D and phosphatidic acid in normal and malignant biological processes, mainly cancer spread.
...
Dr. Ben-Tsion Williger

President and CEO

Ben-Tsion Williger - CEO.